Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin by Garcia, JM et al.
Title Heterosubtype neutralizing responses to influenza A (H5N1)viruses are mediated by antibodies to virus haemagglutinin
Author(s) Garcia, JM; Pepin, S; Lagarde, N; Ma, ESK; Vogel, FR; Chan, KH;Chiu, SSS; Peiris, JSM
Citation Plos One, 2009, v. 4 n. 11
Issued Date 2009
URL http://hdl.handle.net/10722/80147
Rights Creative Commons: Attribution 3.0 Hong Kong License
Heterosubtype Neutralizing Responses to Influenza A
(H5N1) Viruses Are Mediated by Antibodies to Virus
Haemagglutinin
Jean-Michel Garcia1*, Stephanie Pepin2, Nade`ge Lagarde1, Edward S. K. Ma3, Frederick R. Vogel2,
Kwok H. Chan3, Susan S. S. Chiu4, J. S. M. Peiris1,3*
1HKU-Pasteur Research Centre, Hong Kong Special Administrative Region, China, 2 Sanofi Pasteur, Marcy l’Etoile, France, 3Department of Microbiology, University of
Hong Kong, Hong Kong Special Administrative Region, China, 4Department of Paediatrics and Adolescent Medicine, University of Hong Kong, Hong Kong Special
Administrative Region, China
Abstract
Background: It is increasingly clear that influenza A infection induces cross-subtype neutralizing antibodies that may
potentially confer protection against zoonotic infections. It is unclear whether this is mediated by antibodies to the
neuraminidase (NA) or haemagglutinin (HA). We use pseudoviral particles (H5pp) coated with H5 haemagglutinin but not
N1 neuraminidase to address this question. In this study, we investigate whether cross-neutralizing antibodies in persons
unexposed to H5N1 is reactive to the H5 haemagglutinin.
Methodology/Principal Findings: We measured H5-neutralization antibody titers pre- and post-vaccination using the H5N1
micro-neutralization test (MN) and H5pp tests in subjects given seasonal vaccines and in selected sera from European
elderly volunteers in a H5N1 vaccine trial who had detectable pre-vaccination H5N1 MN antibody titers. We found
detectable (titer $20) H5N1 neutralizing antibodies in a minority of pre-seasonal vaccine sera and evidence of a serological
response to H5N1 in others after seasonal influenza vaccination. There was excellent correlation in the antibody titers
between the H5N1 MN and H5pp tests. Similar correlations were found between MN and H5pp in the pre-vaccine sera from
the cohort of H5N1 vaccine trial recipients.
Conclusions/Significance: Heterosubtype neutralizing antibody to H5N1 in healthy volunteers unexposed to H5N1 is
mediated by cross-reaction to the H5 haemagglutinin.
Citation: Garcia J-M, Pepin S, Lagarde N, Ma ESK, Vogel FR, et al. (2009) Heterosubtype Neutralizing Responses to Influenza A (H5N1) Viruses Are Mediated by
Antibodies to Virus Haemagglutinin. PLoS ONE 4(11): e7918. doi:10.1371/journal.pone.0007918
Editor: Paulo Lee Ho, Instituto Butantan, Brazil
Received August 25, 2009; Accepted October 26, 2009; Published November 20, 2009
Copyright:  2009 Garcia et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work described in this paper was fully supported by an Area of Excellence grant from the University Grants Committee of the Hong Kong Special
Administrative Region, China (Project No AoE/M-12/06). JMG was supported by grants from the French Ministry of Health and by the Li Ka Shing Foundation,
Hong Kong, through the RESPARI program (http://www.hku.hk/respari/). The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Competing Interests: Drs Vogel & Pepin are employees of Sanofi Pasteur.
* E-mail: jmgarcia@hku.hk (J-MG); malik@hku.hk (JSMP)
Introduction
Avian influenza (A/H5N1) virus continues to be endemic in
poultry flocks in many Asian and African countries. It occasionally
transmits zoonotically to humans and continues to pose a pandemic
threat. One of the requirements of a pandemic virus is that the
human population is immunologically naive to the new pandemic
haemagglutinin. While protection to influenza is believed to be
subtype specific, it has been shown that exposure to one subtype of
influenza A can induce immunity that is cross-protective against other
subtypes [1–6]. Such broad immune protection is termed ‘‘hetero-
subtypic immunity’’ (HSI) and while it may not provide sterilizing
immunity it may reduce morbidity and mortality. In the context of
pandemic emergence, such heterosubtypic immunity could confer
some level of population immunity and may even prevent some avian
influenza virus subtypes from becoming pandemic viruses, thus
providing an additional barrier to inter-species transmission.
There is some evidence for HSI in humans. Recent influenza A
infection seemed to confer partial protection against symptomatic
disease during the H2N2 pandemic when the pandemic strain did
not share either the HA or NA with the preceding seasonal
influenza viruses [7]. More recently, a retrospective study of the
archived records of laboratory-confirmed cases of influenza before
and during H2N2 pandemic of 1957 also concluded that those
who had been symptomatic during previous influenza season(s)
had accumulated (age dependent) heterosubtypic immunity
reducing attack rate with the pandemic subtype [8]. In general,
such heterosubtypic cross protection is largely believed to be
mediated by cross reactive cell mediated immunity [9]. However
there has also been some suggestion of heterosubtype protection
by neutralizing antibody, at least via antibodies to the NA [10].
Cross-neutralizing antibodies are also relevant in interpreting
sero-epidemiological studies of human infections with avian
influenza viruses such as H5N1 and H9N2 [11]. Approximately
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3% of healthy adult US volunteers in H5N1 vaccine trials had
evidence of antibody to H5N1 virus in their pre-vaccine sera
detected in microneutralization and horse erythrocyte haemagglu-
tination inhibition tests [12]. These antibodies were presumed to be
heterosubtypic antibodies since these volunteers were unlikely to
have been naturally exposed to H5-subtype viruses. Similarly, 24 of
60 volunteers in a H9N2 vaccine clinical trial in the UK had
neutralising antibody to H9N2 virus prior to being vaccinated [11].
The seropositive persons were all UK-residents born before 1969
and it was hypothesised that prior natural exposure to the H2N2
virus subtype may be responsible for some of these cross reactions.
Using an H9N1 reassortant virus, they demonstrated that the
neutralizing activity was directed to the H9-hemagglutinin rather
than the N2 neuraminidase. Finally, recent publications demon-
strated the existence of cross-subtype neutralizing antibodies [13]
directed against a conserved domain of haemagglutinin that acts by
blocking the conformational rearrangement of HA2 sub-domain in
the fusion step of viral entry [14,15].
We have developed, optimised and validated a H5 pseudopar-
ticle-based (H5pp) serological assay for the identification of H5N1
neutralizing antibodies and this assay correlates well with the
conventional micro-neutralization test [16]. As these H5pp only
contain the virus HA, this allows us an opportunity to investigate
neutralizing antibody to the virus HA alone, avoiding the
confounding antibody responses to the NA.
Materials and Methods
Serum samples
Pre and post seasonal influenza vaccine sera from 98 children
who received the Fluarix, GlaxoSmithKline Biologicals, Belgium
containing influenza A/New Caledonia/20/99 (H1N1)-like, A/
California/7/04 (H3N2)-like and B/Shanghai/361/02-like virus
antigens in the winter of 2005 were available from previous studies
on seasonal influenza vaccination [17]. Similar pre and post vaccine
sera from a cohort of community dwelling elderly (n= 118) given
the influenza inactivated split-virion influenza vaccine Vaxigrip
(sanofi pasteur, France) during the winter of 2003 was also used in
this study. The vaccine contained the antigens A/Moscow/10/99
(H3N2); A/New Caledonia/20/99 (H1N1) and B/Hong Kong/
330/2001 [18]. Sanofi pasteur (Swiftwater, PA, USA) provided a
panel of 20 pairs of pre and post vaccination serum samples from
adults vaccinated with seasonal influenza vaccines containing A/
New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and
B/Malaysia/2506/04). They provided pre and post vaccination
sera from volunteers vaccinated withH5N1 vaccines prepared using
A/Vietnam/1194/2004 NIBRG-14 (H5N1) (35 pairs) or A/
Vietnam/1203/2004 seed strains (7 pairs). These served as the
‘‘positive control’’ group of sera. Finally, sanofi pasteur provided us
sera from 16 selected volunteers aged $60 years from a European
H5N1 vaccine clinical trial who had detectable H5N1 MN
antibodies (geometric mean of the two runs measured $20 (1/
dilution)) to A/Vietnam/1194/2004 NIBRG-14 strain prior to
vaccination. Ten elderly random subjects from the same vaccine
trial who did not have antibody titer against A/Vietnam/1194/
2004 NIBRG-14 strain at D0 (two runs measured at D0 titer of
,20) were included as controls (ClinicalTrials.gov NCT00415129).
Post vaccine sera were collected at 21 days post vaccination for
children and adults; and 4 weeks post vaccination for elderly.
H5pp assay
H5 haemagglutinin (A/Cambodia/408008/05; clade 1) pseu-
dotyped lentiviral particles (H5pp) were produced by co-
transfection in HEK-293 cells of plasmids coding for the H5
surface envelope as well as the HIV-1 backbone and the luciferase
reporter gene as described previously [19]. The experimental
parameters affecting the H5pp assay and its clinical validation in a
panel of sera from patients with H5N1 disease and controls have
been previously reported [16]. The H5pp assay was carried out as
follows. MDCK cells (4000 cells/well) were seeded in white 96-
well plates (Perkin Elmer) in 50 mL of DMEM (GIBCO)
complemented with 2.5% foetal bovine serum (Invitrogen) and
1% Penicillin-Streptomycin (Invitrogen) (thereafter called ‘‘com-
plete medium’’). The next day, H5pp were incubated with two-
fold serial dilutions of serum (starting dilution 1:20, 60 mL/well
total) for 2h at 37uC (5% CO2 incubator). Subsequently, 100 mL of
fresh complete medium was added, mixed and 140 mL of the mix
was transferred back to the wells after discarding the old medium.
After 48h incubation at 37uC in a 5% CO2 incubator, 100 mL of
Steady-Glo (Promega) luciferase substrate was added. Lumines-
cence was read 15 minutes later using a Micro-beta (Perkin Elmer)
plate reader. The neutralization titer was defined as the reciprocal
of the serum dilution that neutralized 50% of signal computed by
fitting the 12 dilutions points with the Hill model [20].
Microneutralization test
The micro-neutralization test (HKU-MN) at the HKU
laboratory was done as described previously [21] for the paediatric
and elderly cohort who received the seasonal influenza vaccine.
One hundred tissue culture infectious dose 50 (100 TCID50) of A/
Vietnam/1194/04 (H5N1) virus was mixed with an equal volume
of serial dilutions of serum in quadruplicate, incubated for 1 hour
at 37uC and the virus antibody mixture was added to a preformed
monolayer of MDCK cells. The plates were incubated for 3 days
and the cytopathic effect was visually assessed using an inverted
microscope. Virus back titrations were included to confirm the
challenge dose was as expected. The highest serum dilution
protecting more than half of the wells was taken as the antibody
titer. This method is used for all the results presented in the paper
with the exception of elderly sera from sanofi pasteur vaccination
tested as below.
An alternative microneutralization method (SP-MN) was used
in the sanofi pasteur laboratory for the 26 pairs of sera from sanofi
pasteur H5N1 vaccine trial as described previously [22]. Serum
samples were tested for neutralizing activity against the NIBRG14
(A/Vietnam/1203/2004) (H5N1) reassortant vaccine strain virus
[23]. The key difference in the latter method was that evidence of
virus neutralization was detected by ELISA in virally infected cells
using antibodies to the virus nucleoprotein rather than by
observing viral cytopathic effect. We had previously established
that there was excellent correlation in the antibody titers obtained
by the two MN assays above (unpublished data).
Statistical analysis
In both MN and H5pp tests we have used an antibody titer of
$20 as a positive cut-off for the purpose of these analyses and
negative sera (titers ,20) are scored as 10 for the purpose of
computation. Titers of 80 are generally regarded as a cut-off for
diagnostic purposes, based on the discrimination between H5N1
infected patients and controls [24]. However, our purpose here is
not diagnostics or sero-epidemiology but to understand hetero-
subtypic antibody responses and we consider titers between 20 and
80 to be very relevant in that regard. From a diagnostic point of
view, a positivity cut-off of .20 has similar significance for H5pp
assay as for the MN (data not shown; [16]).
Two-sample unequal variance one-tailed distribution Student’s
t-test was used to assess the differences in geometric titers with
significance level a=0.05.
Heterosubtypic Neutralization
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Ethics statement
All the sera mentioned in this work were provided from past
vaccination trials. Written informed consent were obtained prior
to the start of the trials (consent from parents and the older
children before enrolment for paediatric sera or the subject
themselves for adults). Study protocols were approved by the joint
institutional review board of the University of Hong Kong and
Queen Mary Hospital (Hong Kong) for the paediatrics sera [17];
by the Institutional Review Board of the University of Hong Kong
and Hospital Authority Hong Kong West Cluster for the elderly
sera [18] and by the UK and Belgium IECs (National Research
Ethics Service NHS, Oxfordshire REC B and Ethics Committee of
the University Hospital of Antwerp, respectively) for adults sera
(ClinicalTrials.gov NCT00415129) as detailed in cited references.
All studies complied with the Declaration of Helsinki of 1975, as
revised in 1983.
Results
Neutralizing antibodies titers were measured in parallel by
classical micro-neutralization (MN) and by pseudoparticle-based
neutralization (H5pp) assays for pre and post seasonal influenza
vaccination sera from 98 children, 20 adults and 118 elderly ($60
years old). The antibody responses to seasonal influenza viruses
H1N1, H3N2 and influenza B in these sera have been previously
reported [17,18]. As expected, most subjects were negative (titer
,20) for H5 antibody in both MN and H5pp assays in both pre
and post vaccine sera. Of 118 pre-vaccine sera from subjects aged
$60 years, one (0.8%) had H5-neutralizing antibody in the MN
test, while 8 (6.8%) sera (including the serum with MN antibody)
were sero-positive in the H5pp tests (Table 1). Six additional
individuals sero-converted by the H5pp test after seasonal
influenza vaccination. Of the pre-vaccination sera of 98 children,
none were H5 antibody positive by MN and 1 (1%) was positive by
the H5pp test. Two and 6 children sero-converted respectively by
the MN and H5pp test post vaccination (Table 1).
The pre-vaccine geometric mean H5pp antibody titers (GMT)
for each group were 10.2 for children, 10.4 for adults and 11.5 in
the elderly. The GMT of pre-vaccine sera measured with MN
were no different between the different age groups (p.0.1). There
was a discernible H5pp antibody response to seasonal influenza
vaccine in a few children and elderly subjects. We could measure a
significant increase of GMT after vaccination both in children
(GMT pre vaccination 10.2 versus 11.6 post, p = 0.023) as well as
in elderly (GMT 11.5 pre versus 12.9 post vaccination, p= 0.045)
as shown in Figure 1 and Table 1. Such a response was less
obvious in the MN test and not statistically significant (p.0.2). In
contrast and as expected, there was a marked increase in GMT
post-vaccination with H5N1 clinical candidate vaccines by both
H5pp and MN assays (p,0.001) (Figure 1G and 1H, Table 1).
We next investigated sera collected from European volunteers
above 60 years of age participating in an H5N1 vaccine trial. We
chose 16 subjects who were found to be H5N1 MN antibody
positive pre-vaccination and 10 others who were MN (and HI)
negative (,20) as controls. All 16 volunteers who prior to
vaccination were MN antibody positive were H5pp positive.
One of 10 who was MN negative (MN titer 17) was H5pp-
antibody positive ($20). There was a good linear correlation
between the H5N1 MN and H5pp antibody titers in these sera
(Figure 2A) indicating that the MN H5-antibody titers were largely
explainable by heterosubtypic cross-reactions to the virus HA. The
geometric mean H5pp antibody titer of those 16 individuals with
pre-existing H5 antibody increased from 279.7 to 605.2
(p = 0.038); and from 12.7 to 18.6 (not statistically significant,
p.0.2) in the 10 individuals who were H5-seronegative pre-
vaccination. The serological response to the H5N1 vaccine is
shown in Figure 2B.
Discussion
Prior to immunization, none of 98 children and 1 of 118 (0.8%)
elderly individuals had detectable MN H5-antibody titers while 1/
98 (1%) children and 8/118 (6.8%) elderly persons were positive in
the H5pp test which is known to be a more sensitive assay for
antibody detection [16]. All sera positive in the MN test were also
positive in the H5pp test demonstrating that presumed H5-MN
neutralising activity in human sera is strongly associated with cross
reactivity to the viral HA. None of these persons had known H5N1
disease but since this study cohort were long term residents in
Hong Kong, inadvertent exposure to H5N1 infected poultry
markets or wild birds, though unlikely, cannot be excluded. We
therefore also tested a cohort of 62 adults volunteers from a
seasonal influenza (n= 20) and H5N1 vaccine (n = 42) studies in
Europe where inadvertent exposure to H5N1 virus is highly
improbable. Prior to vaccination, one of these volunteers had
detectable H5 antibody by MN and two were positive for H5pp
antibody (Table 1).
To further investigate these observations on heterosubtypic
neutralizing antibodies, we used selected sera from persons over 60
years of age recruited to a European H5N1 vaccine trial. We
Table 1. Effect of seasonal vaccination on H5 neutralizing antibody titers measured by the microneutralization (MN) and the H5pp
tests in paired sera from children, adults, and elderly after vaccination with seasonal influenza vaccine and H5N1 vaccine.
Type of vaccine Subjects Nc Sera with titer $20 Geometric mean titerd
H5pp MN H5pp MN
pre post pre post pre post p-value pre post p-value
Seasonal Children a 98 1 7 0 2 10.2 11.6 0.023 10.0 10.5 0.252
Adult b 20 1 2 0 0 10.4 11.9 0.196 10.0 10.0 -
Elderly a 118 8 14 1 2 11.5 12.9 0.045 10.1 10.2 0.319
H5N1 Adult b 42 1 39 1 34 10.7 237.6 ,0.001 10.4 41.8 ,0.001
aPatient cohorts from Hong Kong.
bPatient cohorts from Europe.
cN: Number of paired samples.
dFor the computation of geometric mean titers, negative sera (titer,20) are assigned value of 10 (first dilution tested 20). Student’s t-test was used to calculate p-value.
doi:10.1371/journal.pone.0007918.t001
Heterosubtypic Neutralization
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Figure 1. Comparison of H5 neutralizing antibodies tested by MN and H5pp tests for different age groups. Titers were measured from
paired sera of 98 children (A, B), 20 adults (C, D) and 118 elderly (E, F) given seasonal influenza vaccination; (G, H) 42 pairs sera from adults recipient of
H5N1 clinical candidate vaccines. Dashed line marks the positivity criteria (titer$20). Each line represents a paired serum from one individual. Where
more than one person has identical pre and post antibody titers, the number of persons with these overlapping results is denoted as n. The MN titers
were determined at HKU using the MN-HKU method (see methods).
doi:10.1371/journal.pone.0007918.g001
Heterosubtypic Neutralization
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selected 16 individuals whose pre-vaccine sera had detectable
(titers$20) H5N1 MN antibody and 10 persons who did not as
controls. All of the MN positive sera were also positive in the H5pp
test and the titers in the two assays were highly correlated
(Figure 2A, Pearson r=0.734, p,0.001 with all 26 pairs). Only 1
of 10 of the controls (MN antibody negative) was seropositive in
the H5pp assay.
Seasonal influenza vaccine appears to induce heterosubtypic
antibody responses in a minority of individuals by the MN test. In
the Hong Kong vaccine cohorts 2 children (2.0%) and 1 (0.8%)
person in the $60 years cohort had increase in H5 neutralizing
antibodies by MN (Figure 1B and 1F). This was even more notable
in the H5pp test with 6 children (6.1%) and 14 persons $60 years
(5.1%) had H5 antibody responses (Figure 1A and 1E). Again all
the MN sero-conversions are also reflected in the H5pp assay. As
expected, most of the adults given the H5N1 vaccine sero-
converted to H5N1 virus by both MN and H5pp tests (Table 1;
Figure 1G and 1H).
There has been much debate on the mechanisms underlying
heterosubtype cross protection and some have postulated that this
is largely contributed by the virus NA [10,25]. Indeed, DNA
vaccination of mice with the H5N1 virus NA has led to cross
protection against live H5N1 virus challenge. On the other hand,
monoclonal antibodies to HA epitopes that cross neutralise across
subtypes (e.g. H1, H2, H5, H6, H9) have been demonstrated on
the HA and such antibodies cross-protect against H5N1 virus
challenge in mice [13,26]. Our data strongly argue that there are
heterosubtypic neutralising epitopes within the virus HA. Since the
H5pp assay only contains the virus haemagglutinin without the
virus NA or M2 proteins, one can conclude that these H5pp
heterosubtypic cross-reactions are mediated by antibody responses
to epitopes expressed on the virus HA. Published data showed that
such anti-HA heterosubtypic antibodies could be generated in
vitro [15,27]. We showed here they can be detected also in vivo.
Why these cross-subtypic reactions are only manifested by a
minority of individuals is unclear. Possibly the host histocompat-
ibility antigens or other host factors (such as VHI69 gene [28])
may contribute to these unusual heterosubtypic responses.
These findings raise important questions of clinical relevance.
While it is unclear whether these low H5pp antibody titers of 10–
20 have any protective effect, such an effect cannot be ruled out. A
single individual responded with H5N1 MN titers of $256 after
seasonal influenza vaccination suggests that in some occasions,
these heterosubtypic antibodies are within what is accepted to be
within the protective range. More recently, evidence of hetero-
subtypic immunity has been reported [29]. If such heterosubtypic
immunity induced by natural infection with seasonal influenza
viruses or vaccination with seasonal influenza vaccines provides
some cross immunity to H5N1, it may explain a number of
puzzling observations we observe in the epidemiology of H5N1
disease. These include the observation that most people who are
exposed to H5N1 virus fail to get infected by the virus [30], and
also that H5N1 incidence and mortality appears to decrease in
those aged 45 years or older [31]. One may hypothesize that
repeated influenza infection or vaccination leads to a progressive
increase of heterosubtypic immunity that protects humans from
infection with H5N1 infection when they are exposed to it.
Our findings also have implications for sero-diagnosis. While
many of the cross reactive H5 antibody responses we observed
were below the titer of 80 which is generally regarded as a
minimum neutralizing antibody titer to indicate evidence of recent
H5N1 infection, some individuals clearly respond to seasonal
influenza vaccine with substantially higher H5N1 neutralizing
antibody titers. Thus we have to be cognizant of this fact when
interpreting sero-epidemiological data. Although we have used
sera with titers as low as 20 for our analysis, this does not imply
that such titers can be taken as conclusive evidence of exposure to
H5N1 viruses. In fact, our data suggest that low titer H5N1
neutralizing antibodies can very well arise as heterosubtypic
responses to seasonal influenza viruses.
To conclude, using H5pp assay which is more sensitive and
carries the H5 HA without the N1 neuraminidase on the viral
Figure 2. Comparison of titers obtained with H5pp versus MN assays for two panels of paired sera. Titers (reciprocal dilution of serum
that gives 50% neutralization) were determined for sera from elderly (.65 yr) recipient of H5N1 vaccine selected to include 16 with pre-vaccination
MN H5N1 titer $20 and 10 randomly selected seronegative persons with MN titer ,20 and HI ,8. The post vaccination was sampled 21 days post
vaccination. The graph (A) shows the correlation of antibody titers in pre- (circles) and post (square) vaccination sera obtained with the H5 MN (sanofi
pasteur method) and H5pp tests for those who were MN seropositive (black markers) and seronegative (open markers) pre-vaccination. Graph (B)
shows the pre- and post H5N1 vaccination H5pp antibody titers in those with (‘‘seropositive’’) and without (‘‘seronegative’’) pre-vaccine antibody. For
computation, the sera with undetectable antibody titers were given the value of 10. Positivity criterion (titer$20) is represented by dashed lines.
doi:10.1371/journal.pone.0007918.g002
Heterosubtypic Neutralization
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particle, we demonstrated that antibodies directed to haemagglu-
tinin can induce heterosubtypic response to influenza A.
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